Alumis Files for IPO to Fund Phase III Trials of Potential Rival Drug to BMS’ Sotyktu

NASDAQ Market site/iStock

Pictured: Nasdaq building in New York City/iStock, hapabapa

Alumis filed Friday for an initial public offering to raise money for Phase III trials of a potential rival to Bristol Myers Squibb’s Sotyktu (deucravacitinib) and Takeda’s TAK-279.

San Francisco-based Alumis is developing two…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks